Eric Furfine, Ph.D.

Eric Furfine joined Ingenia’s SAB in 2021.  He is also a member of the board of directors of Ingenia. He is co-CEO & CSO of Mosaic Biosciences, Ingenia’s research partner and previously held various leadership roles in biotechnology and pharmaceutical companies, including GSK, Regeneron and BMS. Eric advises Ingenia on pre-clinical development and corporate strategy.

Leo A Kim, M.D., Ph.D.

Leo Kim joined Ingenia’s SAB in 2021. He is an assistant professor of Ophthalmology at Harvard Medical School and a retina surgeon at the Massachusetts Eye and Ear. He is a full time member of the Retina Service with extensive experience in the management of retinal diseases associated with neovascularization or angiogenesis including retinal vein occlusions, diabetic retinopathy, and age-related macular degeneration.

Patricia D’Amore, Ph.D., MBA

Patricia D’Amore joined Ingenia’s SAB in 2021. She is a professor and vice-chair of Basic and Translational Research at Harvard Medical School. Dr. D’Amore is an internationally recognized expert of vascular growth and development and has been at the forefront of angiogenesis research for over three decades. Her current research focuses on understanding the regulation of the development and stabilization of the microvasculature and investigating the pathogenesis of AMD with a focus on inflammation.

Tariq Ghayur, Ph.D.

Tariq Ghayur joined Ingenia’s SAB in 2022. He retired from AbbVie (July 2021) as a Distinguished Research Fellow and currently works as an independent consultant. He has 30+ years’ experience leading multi-disciplinary Biologics discovery programs and developing novel bi- and multi-specific Biologics platforms. Several programs are in various stages of discovery/development pipeline. His research focused on immune modulation for autoimmune and oncology indications and internalization and intracellular trafficking of antibody-receptor complexes.

Thomas M. Coffman, M.D.

Thomas M. Coffman joined Ingenia’s SAB in September 2021.  He is a professor at Duke University Medical Center and served as president of the American Society of Nephrology. His research focuses on the mechanisms of kidney injury in disease states and the role of the kidney in regulation of blood pressure. His research addresses issues that are relevant to chronic disorders such as hypertension, diabetic nephropathy, transplant rejection, and autoimmune diseases.